5:20 PM
 | 
Mar 22, 2013
 |  BC Extra  |  Company News

Halozyme gains on CHMP nod for HyQvia

Halozyme Therapeutics Inc. (NASDAQ:HALO) gained $1.63 (31%) to $6.90 on Friday after EMA's CHMP recommended approval of an MAA for HyQvia from partner Baxter International Inc. (NYSE:BAX) as a replacement therapy for primary immunodeficiency disorders....

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >